Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kidney cancer: drug duo takes on tough tumors

NCT ID NCT04586231

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial compares a combination of two drugs, belzutifan and lenvatinib, against the standard drug cabozantinib in 747 people with advanced kidney cancer that has worsened after initial treatment. The goal is to see if the combo can better slow cancer growth or improve survival. Participants have clear cell renal cell carcinoma that cannot be removed surgically or has spread.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
belzutifan and lenvatinib combination
What this could lead to
If successful, this combination could offer a new treatment option for advanced kidney cancer that has stopped responding to initial therapy, potentially extending life or delaying tumor growth.
What could go wrong
This is a late-stage trial, but the combination may not prove superior to the existing drug cabozantinib. Side effects from the two-drug regimen could be significant, and results may not apply to all kidney cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

747 people

The number who actually took part.

Started

Feb 2021

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC). * Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose. * Measurable disease per RECIST 1.1 criteria as assessed by local study investigator. * Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization. * Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease * Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC. * A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib. * A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm. * Adequately controlled blood pressure. * Adequate organ function. Exclusion Criteria: * A pulse oximeter reading \<92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen. * Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy. * Known central nervous system (CNS) metastases and/or carcinomatous meningitis. * Clinically significant cardiac disease within 6 months of first dose of study intervention. * Prolongation of QTc interval to \>480 ms. * Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable. * Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula. * Moderate to severe hepatic impairment. * History of significant bleeding within 3 months before randomization. * History of solid organ transplantation. * Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study. * Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption). * Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations. * Received colony-stimulating factors \[eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)\] within 28 days before randomization. * Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor. * Prior treatment with lenvatinib. * Prior treatment with cabozantinib. * Currently participating in a study of an investigational agent or using an investigational device. * Active infection requiring systemic therapy. * History of human immunodeficiency virus (HIV) infection. * History of hepatitis B or known active hepatitis C infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced clear cell renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, renal cell

Contacts and locations

Locations

  • ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)

    Chaïdári, Attica, 124 62, Greece

  • Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)

    Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom

  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)

    Orlando, Florida, 32804, United States

  • Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)

    Athens, Attica, 115 28, Greece

  • Amphia Hospital Location Molengracht ( Site 1912)

    Breda, North Brabant, 4818 CK, Netherlands

  • Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)

    Amsterdam, North Holland, 1066 CX, Netherlands

  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0109)

    Calgary, Alberta, T2N 5G2, Canada

  • Asan Medical Center ( Site 4200)

    Seoul, 05505, South Korea

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)

    Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina

  • Athens Medical Center ( Site 3303)

    Athens, Attica, 151 25, Greece

  • Azienda Ospedaliera Policlinico di Bari ( Site 1402)

    Bari, 70124, Italy

  • Azienda Ospedaliera S. Maria di Terni ( Site 1401)

    Terni, 05100, Italy

  • BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)

    Vancouver, British Columbia, V5Z 4E6, Canada

  • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)

    São Paulo, 01321-001, Brazil

  • Blue Ridge Cancer Care - Roanoke ( Site 0043)

    Roanoke, Virginia, 24014, United States

  • Bradfordhill-Clinical Area ( Site 0400)

    Santiago, Region M. de Santiago, 8420383, Chile

  • CHU de Bordeaux- Hopital Saint Andre ( Site 1209)

    Bordeaux, Gironde, 33000, France

  • CHU de Liege ( Site 1102)

    Liège, 4000, Belgium

  • CISSS de la Monteregie-Centre ( Site 0103)

    Greenfield Park, Quebec, J4V 2H1, Canada

  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Cancer & Hematology Centers of Western Michigan ( Site 0018)

    Grand Rapids, Michigan, 49503, United States

  • Cancer Partners of Nebraska ( Site 0086)

    Lincoln, Nebraska, 68516, United States

  • Cedars Sinai Medical Center ( Site 0027)

    Los Angeles, California, 90048, United States

  • Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)

    Wenatchee, Washington, 98801, United States

  • Centre Antoine Lacassagne ( Site 1217)

    Nice, Alpes-Maritimes, 06189, France

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0115)

    Québec, Quebec, G1J 1Z4, Canada

  • Centro Gaucho Integrado de Oncologia ( Site 0304)

    Porto Alegre, Rio Grande do Sul, 90110-270, Brazil

  • Centro de Urología (CDU) ( Site 0803)

    CABA, Buenos Aires, C1120AAT, Argentina

  • Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)

    Craiova, Dolj, 200542, Romania

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Charite Universitaetsmedizin Berlin ( Site 1321)

    Berlin, 10117, Germany

  • Chonnam National University Hwasun Hospital-Oncology ( Site 4203)

    Hwasun, Jeonranamdo, 58128, South Korea

  • Clinique Francois Chenieux ( Site 1210)

    Limoges, Haute-Vienne, 87039, France

  • Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)

    Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

  • Complejo Hospitalario Universitario A Coruna ( Site 1502)

    A Coruña, La Coruna, 15006, Spain

  • Cross Cancer Institute ( Site 0111)

    Edmonton, Alberta, T6G 1Z2, Canada

  • Duke Cancer Institute ( Site 0096)

    Durham, North Carolina, 27710, United States

  • Emory University Hospital ( Site 0012)

    Atlanta, Georgia, 30322, United States

  • Erasmus MC ( Site 1913)

    Rotterdam, South Holland, 3015 GD, Netherlands

  • European Interbalkan Medical Center-Oncology Department ( Site 3300)

    Thessaloniki, 570 01, Greece

  • FSBI United Hospital with Polyclinic ( Site 2613)

    Moscow, Moscow, 119285, Russia

  • Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)

    Prague, Praha 4, 140 59, Czechia

  • Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)

    Hradec Králové, 500 05, Czechia

  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)

    Prague, Praha 5, 150 06, Czechia

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)

    Roma, 00168, Italy

  • Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)

    Schiedam, South Holland, 3118 JH, Netherlands

  • Fujita Health University Hospital ( Site 5003)

    Toyoake, Aichi-ken, 470-1192, Japan

  • Fundacion Colombiana de Cancerología Clinica Vida ( Site 0505)

    Medellín, Antioquia, 050030, Colombia

  • Fundación Cardiovascular de Colombia ( Site 0501)

    Piedecuesta, Santander Department, 681017, Colombia

  • GenesisCare North Shore ( Site 4011)

    St Leonards, New South Wales, 2065, Australia

  • Georgetown University Medical Center ( Site 0006)

    Washington D.C., District of Columbia, 20007, United States

  • Grand Hopital de Charleroi ( Site 1104)

    Gilly, Hainaut, 6060, Belgium

  • HELIOS Klinikum Berlin-Buch ( Site 1311)

    Berlin, 13125, Germany

  • HYKS ( Site 1800)

    Helsinki, Uusimaa, 00290, Finland

  • Hadassah Medical-Oncology department ( Site 2609)

    Moscow, Moscow Oblast, 121205, Russia

  • Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)

    The Hague, South Holland, 2545 AA, Netherlands

  • Hamamatsu University Hospital ( Site 5004)

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)

    Hamilton, Ontario, L8V 5C2, Canada

  • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)

    Saint Louis Park, Minnesota, 55426, United States

  • Helios Klinikum Erfurt GmbH ( Site 1315)

    Erfurt, Thuringia, 99089, Germany

  • Hopital Tenon ( Site 1213)

    Paris, 75020, France

  • Hopitaux Universitaires de Geneve HUG ( Site 1602)

    Geneva, Canton of Geneva, 1211, Switzerland

  • Hopitaux Universitaires de Strasbourg- Hopital de Hautepierre ( Site 1218)

    Strasbourg, Bas-Rhin, 67200, France

  • Hospital Británico de Buenos Aires-Oncology ( Site 0801)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina

  • Hospital Clinic i Provincial ( Site 1500)

    Barcelona, 08036, Spain

  • Hospital Clinico San Carlos... ( Site 1504)

    Madrid, 28040, Spain

  • Hospital General Universitario Gregorio Maranon ( Site 1505)

    Madrid, 28009, Spain

  • Hospital Paulistano - Amil Clinical Research ( Site 0308)

    São Paulo, 01321-001, Brazil

  • Hospital Santa Creu i Sant Pau ( Site 1501)

    Barcelona, 08041, Spain

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)

    Madrid, Madrid, Comunidad de, 28041, Spain

  • Hospital Virgen del Rocio ( Site 1503)

    Seville, 41013, Spain

  • Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)

    Salt Lake City, Utah, 84112, United States

  • IRCCS Ospedale San Raffaele ( Site 1409)

    Milan, 20132, Italy

  • Illinois Cancer Care, PC ( Site 0008)

    Peoria, Illinois, 61615, United States

  • Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)

    London, London, City of, W6 8RF, United Kingdom

  • Institut Claudius Regaud ( Site 1215)

    Toulouse, Haute-Garonne, 31059, France

  • Institut Jean Godinot ( Site 1216)

    Reims, Ain, 51726, France

  • Institut Jules Bordet ( Site 1103)

    Anderlecht, Bruxelles-Capitale, Region de, 1070, Belgium

  • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)

    Saint-Herblain, Loire-Atlantique, 44805, France

  • Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)

    Angers, Maine-et-Loire, 49055, France

  • Institute of Science Tokyo Hospital ( Site 5009)

    Bunkyo-ku, Tokyo, 113-8510, Japan

  • Instituto Alexander Fleming ( Site 0800)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina

  • Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)

    Bogotá, Cundinamarca, 111511, Colombia

  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)

    Cluj-Napoca, Cluj, 400015, Romania

  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)

    Cluj-Napoca, Cluj, 400015, Romania

  • Ironwood Cancer & Research Centers ( Site 0077)

    Chandler, Arizona, 85224, United States

  • Istituti Clinici Scientifici Maugeri Spa ( Site 1403)

    Pavia, 27100, Italy

  • Istituto Clinico Humanitas Research Hospital ( Site 1406)

    Rozzano, Milano, 20089, Italy

  • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)

    Meldola, Forli-Cesena, 47014, Italy

  • Ivanovo Regional Oncology Dispensary ( Site 2616)

    Ivanovo, Ivanovo Oblast, 153040, Russia

  • James Lind Centro de Investigacion del Cancer ( Site 0402)

    Temuco, Araucania, 4800827, Chile

  • Kantonsspital Graubuenden ( Site 1600)

    Chur, Kanton Graubünden, 7000, Switzerland

  • Keio University Hospital ( Site 5011)

    Tokyo, 160-8582, Japan

  • Kindai University Hospital ( Site 5010)

    Sakai, Osaka, 590-0197, Japan

  • Kingston Health Sciences Centre ( Site 0105)

    Kingston, Ontario, K7L 2V7, Canada

  • Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)

    Vienna, State of Vienna, 1160, Austria

  • Klinik fuer Urologie ( Site 1303)

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Klinikum Nuernberg Nord ( Site 1300)

    Nuremberg, Bavaria, 90419, Germany

  • Kobe City Medical Center General Hospital ( Site 5017)

    Kobe, Hyōgo, 650-0047, Japan

  • Krankenhaus Martha Maria Halle-Doelau ( Site 1314)

    Halle, Saxony-Anhalt, 06120, Germany

  • Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)

    Vienna, 1020, Austria

  • Kyushu University Hospital ( Site 5005)

    Fukuoka, 812-8582, Japan

  • Lahey Hospital & Medical Center ( Site 0090)

    Burlington, Massachusetts, 01805, United States

  • Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)

    Allentown, Pennsylvania, 18103, United States

  • Levine Cancer Institute ( Site 0004)

    Charlotte, North Carolina, 28204, United States

  • Liga Norte Riograndense Contra o Cancer ( Site 0313)

    Natal, Rio Grande do Norte, 59151600, Brazil

  • Lyell McEwin Hospital ( Site 4004)

    Elizabeth Vale, South Australia, 5112, Australia

  • MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)

    Krasnogorsk, Moscow Oblast, 143442, Russia

  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)

    Brno, Brno-mesto, 656 53, Czechia

  • Mater Misericordiae University Hospital ( Site 3201)

    Dublin, D07 R2WY, Ireland

  • Mater Private Hospital - Dublin ( Site 3202)

    Dublin, D07 R2WY, Ireland

  • Medical Oncology Ospedale San Donato ( Site 1404)

    Arezzo, 52100, Italy

  • Medisch Centrum Leeuwarden ( Site 1905)

    Leeuwarden, Provincie Friesland, 8934 AD, Netherlands

  • Medizinische Universität Wien ( Site 1021)

    Vienna, 1090, Austria

  • Medizinische Universitätsklinik Graz ( Site 1051)

    Graz, Styria, 8036, Austria

  • Memorial Sloan Kettering Cancer Center ( Site 0055)

    New York, New York, 10065, United States

  • Mount Vernon Cancer Centre ( Site 3101)

    Northwood, London, City of, HA6 2RN, United Kingdom

  • Musgrove Park Hospital ( Site 3103)

    Taunton, Somerset, TA1 5DA, United Kingdom

  • NCT-Department of Medical Oncology ( Site 1320)

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Nara Medical University Hospital ( Site 5002)

    Kashihara, Nara, 634-0813, Japan

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 2403)

    Krakow, Lesser Poland Voivodeship, 31-115, Poland

  • National Cancer Center Hospital East ( Site 5000)

    Kashiwa, Chiba, 2778577, Japan

  • Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 2204)

    České Budějovice, South Bohemian Region, 37001, Czechia

  • Niigata University Medical & Dental Hospital ( Site 5013)

    Niigata, 951-8520, Japan

  • Nippon Medical School Hospital ( Site 5006)

    Tokyo, 113-8603, Japan

  • Norton Cancer Institute - St. Matthews ( Site 0065)

    Louisville, Kentucky, 40207, United States

  • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)

    Nottingham, England, NG5 1PF, United Kingdom

  • Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)

    Linz, Upper Austria, 4020, Austria

  • Orlando Health, Inc. ( Site 0035)

    Orlando, Florida, 32806, United States

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5016)

    Osaka, 541-8567, Japan

  • Ospedale Maggiore Borgo Trento ( Site 1408)

    Verona, 37126, Italy

  • Ospedale San Luigi Gonzaga ( Site 1405)

    Orbassano, Torino, 10043, Italy

  • Parkview Cancer Institute ( Site 0088)

    Fort Wayne, Indiana, 46845, United States

  • Peninsula Health Frankston Hospital ( Site 4001)

    Frankston, Victoria, 3199, Australia

  • Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)

    Melbourne, Victoria, 3000, Australia

  • Providence Saint John's Health Center ( Site 0083)

    Santa Monica, California, 90404, United States

  • R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)

    Lake Success, New York, 11042, United States

  • Royal United Hospital Bath England ( Site 3108)

    Bath, Bath And North East Somerset, BA1 3NG, United Kingdom

  • Rush University Medical Center ( Site 0040)

    Chicago, Illinois, 60607, United States

  • Rutgers Cancer Institute of New Jersey ( Site 0078)

    New Brunswick, New Jersey, 08903, United States

  • SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)

    Moscow, Moscow, 125130, Russia

  • Samsung Medical Center ( Site 4201)

    Seoul, 06351, South Korea

  • Sanatorio Británico-Clinical Oncology Department ( Site 0802)

    Rosario, Santa Fe Province, 2000, Argentina

  • Sanatorio Parque ( Site 0806)

    Rosario, Santa Fe Province, S2000DSV, Argentina

  • Sapporo Medical University Hospital ( Site 5008)

    Sapporo, Hokkaido, 060-8543, Japan

  • Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)

    Seattle, Washington, 98109, United States

  • Singleton Hospital ( Site 3111)

    Swansea, Wales, SA2 8QA, United Kingdom

  • Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)

    Valledupar, Cesar Department, 200001, Colombia

  • Southend University Hospital ( Site 3112)

    Southend, Essex, SS0 0RY, United Kingdom

  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)

    Orange, California, 92868, United States

  • Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)

    Toronto, Ontario, M4N 3M5, Canada

  • TYKS ( Site 1802)

    Turku, Southwest Finland, 20520, Finland

  • Tallaght University Hospital ( Site 3200)

    Dublin, D24NR0A, Ireland

  • Tampereen yliopistollinen sairaala ( Site 1801)

    Tampere, Pirkanmaa, 33520, Finland

  • The Moncton Hospital ( Site 0101)

    Moncton, New Brunswick, E1C 6Z8, Canada

  • The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)

    Ottawa, Ontario, K1H 8L6, Canada

  • The University of Osaka Hospital ( Site 5012)

    Suita, Osaka, 565-0871, Japan

  • Toho University Sakura Medical Center ( Site 5014)

    Sakura, Chiba, 285-8741, Japan

  • Tokyo Women's Medical University Adachi Medical Center ( Site 5015)

    Tokyo, 123-8558, Japan

  • Toranomon Hospital ( Site 5001)

    Minato-ku, Tokyo, 105-8470, Japan

  • Tulane University School of Medicine ( Site 0098)

    New Orleans, Louisiana, 70112, United States

  • UCLA Hematology/Oncology - Santa Monica ( Site 0048)

    Los Angeles, California, 90404, United States

  • UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)

    Pátrai, Achaia, 26504, Greece

  • UZ Gent ( Site 1100)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • UZ Leuven ( Site 1101)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Universitaetsklinikum Aachen AOER ( Site 1317)

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Universitaetsklinikum Frankfurt ( Site 1301)

    Frankfurt am Main, Hesse, 60590, Germany

  • Universitaetsklinikum des Saarlandes ( Site 1305)

    Homburg/ Saar, Saarland, 66421, Germany

  • Universitaetsspital Zuerich ( Site 1601)

    Zurich, Canton of Zurich, 8001, Switzerland

  • Universitair Medisch Centrum Utrecht ( Site 1910)

    Utrecht, 3584 CX, Netherlands

  • University Cancer & Blood Center, LLC ( Site 0057)

    Athens, Georgia, 30607, United States

  • University of California, Irvine ( Site 0029)

    Orange, California, 92868, United States

  • University of Mississippi Medical Ctr ( Site 0037)

    Jackson, Mississippi, 39213, United States

  • University of Texas, Southwestern Medical Center ( Site 0015)

    Dallas, Texas, 75235, United States

  • University of Vermont Medical Center ( Site 0001)

    Burlington, Vermont, 05401, United States

  • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)

    Poznan, Greater Poland Voivodeship, 60-569, Poland

  • Volgograd Regional Uronephrological Center ( Site 2615)

    Volzhsky, Volgograd Oblast, 404120, Russia

  • Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)

    Yaroslavl, Yaroslavl Oblast, 150054, Russia

  • Yokohama City University Hospital ( Site 5007)

    Yokohama, Kanagawa, 236-0004, Japan

  • Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)

    Sittard-Geleen, Limburg, 6162 BG, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.